Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine - Centre de recherche des Cordeliers Accéder directement au contenu
Article Dans Une Revue Frontiers in Immunology Année : 2021

Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine

Jules Russick
Maxime Meylan
Eric Tartour

Résumé

SARS-CoV-2 infection leads to a highly variable clinical evolution, ranging from asymptomatic to severe disease with acute respiratory distress syndrome, requiring intensive care units (ICU) admission. The optimal management of hospitalized patients has become a worldwide concern and identification of immune biomarkers predictive of the clinical outcome for hospitalized patients remains a major challenge. Immunophenotyping and transcriptomic analysis of hospitalized COVID-19 patients at admission allow identifying the two categories of patients. Inflammation, high neutrophil activation, dysfunctional monocytic response and a strongly impaired adaptive immune response was observed in patients who will experience the more severe form of the disease. This observation was validated in an independent cohort of patients. Using in silico analysis on drug signature database, we identify differential therapeutics that specifically correspond to each group of patients. From this signature, we propose a score—the SARS-Score—composed of easily quantifiable biomarkers, to classify hospitalized patients upon arrival to adapt treatment according to their immune profile.
Fichier principal
Vignette du fichier
fimmu-12-701273.pdf (5.12 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03345484 , version 1 (15-09-2021)

Identifiants

Citer

Jules Russick, Pierre-Emmanuel Foy, Nathalie Josseaume, Maxime Meylan, Nadine Ben Hamouda, et al.. Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine. Frontiers in Immunology, 2021, 12, pp.701273. ⟨10.3389/fimmu.2021.701273⟩. ⟨hal-03345484⟩
61 Consultations
41 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More